The DOI matches its Crossref record; 26 of the 30 references it cites were found in a registry or an index.
Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia
Abstract
An unusual nephropathy presumably induced by abnormal lipid metabolism is described in a 57-year-old woman who presented with proteinuria and edema. Histology at renal biopsy was characterized by marked dilatation of capillary lumina. Sudan staining and electron microscopy demonstrated lipid droplets occupying the capillary lumina. The patient had no particular clinical symptoms of lipidosis, but hyperlipoproteinemia similar to type III was suggested by lipid profiles. The nephropathy is thought to be an inherited disorder because proteinuria was detected in her sisters and similar renal histology and lipid profile were observed in one of her sisters. This is believed to be the first detailed report of glomerular lipoprotein thrombi.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lipoprotein glomerulopathy (LPG) was initially reported in Japan [2] and later known to be associated with various heterozygous ApoE variants, e.g., ApoE Sendai [3] and ApoE Kyoto [4].”
From Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2 (2018) · cites this paper as [2]
In the citing paper
“Diagnosis of LPG relies primarily on renal pathology, with typical lipoprotein thrombosis within dilated glomerular capillary loops.”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is an inherited glomerular disease caused by mutations in the APOE gene, usually with clinical manifestations of dysregulated lipid metabolism, proteinuria, and renal insufficiency.”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“The first 2 cases of LPG were reported by Japanese scholar Saito et al. in the same family in 1989 [1].”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“Massive lipoprotein thrombi in the lumens of dilated glomerular capillaries are the typical pathological manifestation of LPG3).”
From The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy (2018) · cites this paper as [3]
In the citing paper
“In contrast to apoE2 homozygote glomerulopathy, LPG is characterized by dilation of glomerular capillaries with lipoprotein thrombi showing lamellar formation, directly inducing glomerular damage without inducing foamy changes68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“LPG is a rare renal disease first reported in Japan in 1989 68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“LPG was initially identified as a glomerular disease associated with type III HLP68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“Histological features are the most important evidence for the diagnosis of LPG [2].”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Immunofluorescence microscopy shows positive staining of ApoE and ApoB in lumen thrombotic substances.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Nearly half of mutations occurred in the LDL-receptor binding site (LRBS), such as ApoE Sendai (Arg145Pro) [2], ApoE Chicago (Arg147Cys) [16], ApoE Guangzhou (Arg150Pro)[17], ApoE Modena (Arg 150Cys) [11], ApoE Okayama (Arg150Gly) [18], ApoE Tokyo (Del 141-143) [19], and ApoE Maebasi (Del 142-144). These mutations might result in reduced binding capacity of ApoE protein to LDL receptor.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Under light microscopy, the capillary lumen is typically highly dilated and filled with lightly stained reticular material.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is a rare inherited disease characterized by histopathological features of lipoprotein thrombi in dilated glomerular capillaries and type III like hyperlipoproteinemia with heterozygous mutation of the apolipoprotein (apo) E gene.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [1]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is a condition first described in Japan in 1989.1”
From Lipoprotein Glomerulopathy, First Case Report from Canada (2022) · cites this paper as [1]
Citations
Cites
Hatch, F. T., & Lees, R. S. (1968) · Advances in lipid research · doi:10.1016/b978-1-4831-9942-9.50008-5 · Cited by 1,235
Renal Disease. Classification and Atlas of Glomerular Diseases.
(1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-801_2 · Cited by 675
Apolipoprotein E polymorphism in health and disease
Utermann, G. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90610-7 · Cited by 389
LACTIC ACIDOSIS AND HYPERLACTATÆMIA
Cohen, R. D., Woods, H. F., & Alberti, K. G. M. M. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91784-x · Cited by 222
Type III Hyperlipoproteinemia: An Analysis of Two Contemporary Definitions
Fredrickson, D. S., MORGANROTH, J., & LEVY, R. I. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-150 · Cited by 177
Bouthillier, D., Sing, C. F., & Davignon, J. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37920-7 · Cited by 176
The clinical spectrum of renal cholesterol embolization
Smith, M. C. F., Ghose, M., & Henry, A. R. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90290-4 · Cited by 147
Hazzard, W. R., Porte, D., & Bierman, E. L. (1972) · Metabolism · doi:10.1016/0026-0495(72)90031-5 · Cited by 134
The Progressive nature of renal disease
Mitch, W. E. (1986) · Churchill Livingstone eBooks · Cited by 131
Grond, J., Weening, J. J., & Elema, J. D. (1984) · PubMed · Cited by 107
Research works printed but not linked: 2
- Hatch, 1986, Practical methods for plasma lipoprotein analysis, Adv Lipid Res, 6, 1
- Amatruda, 1974, Type III hyperlipoproteinemia with mesangial foam cells in renal glomeruli, Arch Pathol, 98, 51
Cited by
Sorted by citations
Lipid abnormalities in renal disease
Appel, G. B. (1991) · Kidney International · doi:10.1038/ki.1991.22 · Cited by 278
Keane, W. F. (1994) · Kidney International · doi:10.1038/ki.1994.349 · Cited by 205
Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment
Wheeler, D. C., & Bernard, D. B. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80994-2 · Cited by 186
Systemic and renal lipids in kidney disease development and progression
WAHL, P. W., Ducasa, G. M., & Fornoni, A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00375.2015 · Cited by 147
Oikawa, S., Matsunaga, A., Saito, T., Sato, H., Seki, T., Hoshi, K., Hayasaka, K., Kotake, H., Midorikawa, H., Sekikawa, A., et al. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v85820 · Cited by 103
Self-citation
Metadata
- Authors
- Saito, T., Sato, H., Kudo, K.-I., Oikawa, S.-I., Shibata, T., Hara, Y., Yoshinaga, K., & Sakaguchi, H.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Saito, Takao
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 1989-02
- Volume
- 13
- Issue
- 2
- Pages
- 148-153
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W1964757582
- Semantic Scholar
- da403efad9eaea0bf6dbcbfdb6bf2659875fab39
- Cited by
- 148
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 1 · 2016: 6 · 2015: 4 · 2014: 8 · 2013: 8 · 2012: 5
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- lipoprotein glomerulopathy, type III hyperlipoproteinemia, familial hypercholesterolemia, proteinuria, lipid metabolism disorders, renal biopsy histology
- MeSH terms
- Adult, Capillaries, Female, Humans, Hyperlipoproteinemias, Immunoglobulin G, Immunoenzyme Techniques, Kidney Diseases, Kidney Glomerulus, Lipoproteins, LDL, Middle Aged, Sclerosis, Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
